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Primary ovarian insufficiency (POI) affects 1% of women before 40 years of
age. The recent leap in genetic knowledge obtained by next generation
sequencing (NGS) together with animal models has further elucidated its
molecular pathogenesis, identifying novel genes/pathways. Mutations of
>60 genes emphasize high genetic heterogeneity. Genome-wide association
studies have revealed a shared genetic background between POI and repro-
ductive aging. NGS will provide a genetic diagnosis leading to genetic/thera-
peutic counseling: first, defects in meiosis or DNA repair genes may predispose
to tumors; and second, specific gene defects may predict the risk of rapid loss
of a persistent ovarian reserve, an important determinant in fertility preserva-
tion. Indeed, a recent innovative treatment of POI by in vitro activation of
dormant follicles proved to be successful.
Introduction
Primary ovarian insufficiency (POI), affects 1% of women before 40 years of age, thus being a
relatively frequent syndrome [1]. POI is often diagnosed too late, causing irreversible
impairment to the fertility and well-being of the affected women. Recent data indicate that
POI is associated with significant morbidity and mortality. Several of these risks are direct
consequences of extra-ovarian defects, generated by the gene mutations that underlie some
forms of POI [2]. The clinical relevance of POI has exponentially increased only very recently,
particularly in economically advanced countries, due to the frequent choice of women to
conceive after 30 years of age and the increased life expectancy.
POI can manifest as pubertal delay and primary amenorrhea (PA), secondary amenorrhea (SA),
or oligomenorrhea of 4 months. Recurrence of menses and pregnancies can occur in up to
22% of cases with SA for up to 4 months [3], but spontaneous resumption of follicle activity is
exceptional in cases with long-lasting SA. The POI-associated hypergonadotropic hypogo-
nadisms is defined as elevation of follicle-stimulating hormone (FSH) (see Glossary) 
25 IU/L confirmed twice, 30 days apart, in women with SA [1]. The ovarian reserve (OR) can
be evaluated by transvaginal ovarian ultrasound (US) with antral follicular count and/or by anti-
Müllerian hormone (AMH) determination. In both PA and SA cases, it is possible to uncover a
certain OR by US and AMH measurement [4].
Highlights
The mechanisms underlying the for-
mation of the ovarian reserve are gen-
erally well conserved, from Drosophila
to mammals. Owing to this high
degree of conservation, factors shown
to regulate the ovarian reserve in
mouse models are all potential candi-
dates for identifying mutations asso-
ciated with POI in humans.
With the generation of genetically
modified mice, much insight has been
gained into the mechanisms that con-
trol the formation of the ovarian reserve
and trigger the activation of primordial
follicles.
Comparison with animal models is
complicated by the fact that the phe-
notype of complete gene deletion in
knockout models may not be
mimicked by single gene mutations.
Recently innovative treatment for POI
based on in vitro activation of the dor-
mant primordial follicular pool has
been developed.
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Low/undetectable AMH indicates a dramatic diminution of the OR, predicting poor success of
fertility preservation. However, follicular activity and pregnancy were rescued in POI patients
with undetectable serum AMH after in vitro activation (IVA) and autotransplantation of fresh
tissue [5].
Menstrual irregularities, such as oligoamenorrhea or polymenorrhea, can anticipate the onset of
SA, but not as a rule.
Many clinicians are unaware of the advantages of early POI diagnosis and fail to provide
integrated personal care to address all the clinical needs. Here, we review the pathophysiology,
genetics and treatment of POI in order to shed light on: (i) the manifestations that should alert
clinicians, and (ii) the novel multidisciplinary approaches for improved clinical management.
Iatrogenic POI frequently occurs in cancer survivors of young age. A variety of environmental
factors, such as infections or pollutants like phthalates, bisphenol A, and polycyclic aromatic
hydrocarbons from cigarette smoke, have a harmful impact on reproduction and are implicated
in about 10% of POI [6]. Pollutants can affect ovarian follicles mainly by binding to estrogen or
aryl hydrocarbon receptors, severely affecting follicle growth and viability [7]. Moreover,
pollutants can cause germline epigenetic modifications, thereby accounting for transgenera-
tional inheritance of reduced OR [8]. About 5%–30% of POI may have autoimmune origin [9],
which is of potential interest because an early diagnosis may allow prompt treatment and
eventually prevent damage to the OR.
The incidence of familial cases of premature ovarian failure was reported to vary from 4% to
31% [10,11]. Thorough evaluation of alleged affected relatives showed a lower incidence
(12.7%) than the original family history suggested [12]. Pedigree studies on affected families
showed a mode of inheritance suggestive of autosomal dominant or recessive transmission
with highly variable expressivity or X-linked inheritance with incomplete penetrance [13].
Approximately 2–6% of women with sporadic POI have a premutation of the FMR1 gene
[14]. Other known genetic causes are responsible for a small proportion of POIs.
Most causes of POI are unknown. Understanding the underlying molecular mechanisms is
essential to develop strategies for prevention, early diagnosis, and improved management of
POI.
A great leap in the genetics of POI was achieved by the major methodological progress of next
generation sequencing (NGS) and in particular whole exome sequencing (WES). The
knowledge of more than 60 genes has enabled genetic diagnosis by NGS and provided a flow
chart for the diagnosis and treatment of POI (see below). A novel innovative treatment of the
infertility of these patients has recently emerged.
Establishment of the OR
Primordial follicles (PFs) constitute the entire OR. Mechanisms that regulate the formation of the
PF pool and the rate by which it is used will determine the duration of the fertile lifespan
(Figures 1 and 2). OR formation is a similar process in humans and mice, and in recent years,
much insight has been gained into the molecular mechanisms involved.
At 20 weeks of gestation, a pair of human ovaries contains close to 7 million germ cells [15]. A
rapid loss of follicles in fetal life results in about 1–2 million oocytes at birth. Prior to puberty, the
number declines further, to 300 000–400 000. During reproductive life, the number declines
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steadily until a critical threshold of 1000 PFs is reached [15]. Below this threshold, ovulations
cannot be supported, yielding menopause.
Oocytes derive from primordial germ cells (PGCs), which emerge from the extraembryonic
mesoderm and migrate to the genital ridge (Figure 1). Upon arrival in the gonad, the PGCs will
yield interconnected oogonia which, together with aggregation of germ cells, create so-called
germ cell cysts [16]. Somatic cell-derived factors, in particular bone morphogenetic proteins
(BMPs) and Wnt3/b-catenin, control the commitment, migration, and proliferation of PGCs.
These signaling pathways induce the reacquisition of pluripotency, which is driven by Prdm1
and Prdm14. Subsequently, pluripotency genes (Pou5F1 encoding Oct4, Nanog, Klf4, Lin 28a)
and germline specific genes (early genes: Nanos3, Kitlg, Tfapc2, Dppa3; late genes: Ddx4 or
Vasa, Mael, Dazl) play important roles in the migration, proliferation, and survival of PGCs [16].
After cessation of mitosis, the oogonia enter meiosis (13.5 days postconception in mouse and
asynchronously 10–12 weeks of gestation in humans) and become oocytes (Figures 1 and 2).
They will progress through the initial stages of prophase I until arrest in the diplotene stage of
prophase I. The initiation of meiosis is dependent on expression of Dazl, which induces
responsiveness to retinoic acid, which in turn induces Stra8 (stimulated by retinoic acid)-
dependent and -independent pathways, and subsequently the activation of the synaptonemal
complex (SC) proteins Sycp1, 2, and 3. Recently, Taf4b was identified as an upstream regulator
of several meiotic genes, including Stra8 and Dazl, in both mice and women [17]. Additionally it
recently appeared that post-transcriptional mechanisms involving the Ythdc2/Meioc complex
are mandatory for the proper mitotic/meiotic transition [18,19].
The next developmental step in follicle formation is the breakdown of germ cell cysts between
E17.5 and 5 days postpartum in mice and at midgestation (10–13 weeks of gestation) in
humans (Figure 1). Upon breakdown, pregranulosa cells are recruited to encapsulate a single
oocyte to form PF, and oocytes undergo meiotic arrest. Gdf9, Bmp15, FoxL2, Nobox, Figla,
Notch2, and Adam10 include some of the factors that affect the timing of cyst breakdown and
differentiation of pregranulosa cells [20,21]. Furthermore, estrogen signaling plays an inhibitory
role in cyst breakdown [22]. At the cessation of mitosis, the number of oogonia has increased
exponentially. However, it is estimated that during cyst breakdown, two-thirds of the oocytes
are lost through programmed cell death, including apoptosis and autophagy [23].
Genetic modification in mice has been beneficial for identification of the crucial genes in
establishment of the OR. Mutations in several of these genes have been identified in women
with POI.
Recent Advances in the Genetics of POI in Humans
The genetic causes of POI are highly heterogeneous, with isolated or syndromic forms.
Reproductive and extra-reproductive features of syndromic POI are described in Table 1.
The genes involved are listed in Figures 1–3 and Table 1.
Meiosis, DNA Repair, and POI
Mutations of meiotic and DNA repair genes are responsible for syndromic and nonsyndromic
POI (Figures 2 and 3). There have been recent major advances in the identification of these
genes as a cause of POI through NGS studies.
Oocytes enter into and progress through meiosis prophase I during fetal life. Mutations in
meiotic genes usually impair meiotic progression and trigger oocyte death, as evidenced by
several mouse models [24].
Glossary
Anti-Müllerian hormone (AMH): a
growth factor produced by the
granulosa cells of growing follicles.
Serum AMH level is an indirect
marker of the ovarian reserve and
declines with increasing age.
Follicle-stimulating hormone
(FSH): a pituitary-derived hormone
that stimulates estrogen production,
follicle growth, and selection of the
preovulatory follicle. Serum FSH
levels are elevated upon ovarian
aging due to the loss of negative
feedback signals. Normal FSH
concentrations (IU/l) are: during
follicular phase, 3.5–9.0; ovulatory
phase, 7.0–21.5; luteal phase, 1.7–
7.0; postmenopause, 26–140.
Homologous recombination (HR):
a process that assures faithful repair
of double strand breaks, one of the
most dangerous DNA damages. HR
relies on the invasion of a similar
DNA matrix (the homologous
chromosome during meiosis) as a
template to repair the broken DNA.
The products of this repair can either
be a local replacement of DNA
sequence or exchange of large
chromosome fragments, respectively
termed non-crossover and
crossover. The meiotic crossovers
are mandatory for proper segregation
of chromosomes, thus precisely
halving the genome in gametes.
In vitro activation (IVA): although
menstrual cycles cease in POI
patients, some of them retain
residual dormant ovarian follicles. A
new infertility treatment has been
developed, which enables POI
patients to conceive using their own
eggs, by activation of the residual
dormant follicles through in vitro
manipulation of signaling pathways
responsible for follicular quiescence.
Luteinizing hormone (LH): a
pituitary-derived hormone that
triggers ovulation. Serum LH levels
increase upon ovarian aging due to
the loss of negative feedback signals.
Meiosis: meiosis is the universal
cellular process in eukaryotes that
allows formation of the haploid
reproductive cells.
DNA double strand breaks
(DSBs): DSBs are programmed DNA
breaks generated early during
prophase I and catalyzed by the
sporulation 11 homolog (SPO11)
enzyme. DSBs are concentrated in
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‘hotspots’ designated by PR domain
containing 9 (PRDM9), through the
deposition of trimethylation on lysine
4 of histone 3.
Next generation sequencing
(NGS): also known as high-
throughput sequencing, describes
modern sequencing technologies
that allow the sequencing of
thousands to millions of DNA
molecules simultaneously. It allows
sequencing multiple genes and
multiple individuals at the same time.
Nonhomologous end-joining
(NHEJ): a DSB repair pathway often
opposed to HR. NHEJ directly ligates
broken DNA ends together. It is
believed to result in low repair fidelity
in the absence of a homologous
sequence to guide DNA repair, as in
HR.
Ovarian reserve (OR): a term
describing the quality and number of
resting oocytes within primordial
follicles, and considered as a
female’s reproductive potential.
PI3K/Akt signaling pathway: the
phosphatidylinositol 3-kinase/Akt/
mammalian target of rapamycin
(PI3K/Akt/mTOR) signaling pathway,
regulating various stages of
folliculogenesis. Studies in most
genetic mouse models have revealed
an essential role of this pathway in
primordial follicle activation.
Primordial germ cells (PGCs): the
primary cells that form the
progenitors of gametes. PGCs will
populate the embryonic gonads and
differentiate into either oocytes or
spermatocytes.
Whole exome sequencing (WES):
sequencing by NGS, the protein-
coding region of the human genome
(exome) that represents <2% of the
genome, but contains most known
disease-related variants.
During prophase I, meiosis requires the establishment of the SC and the generation and repair
of DNA double strand breaks (DSBs) [25]. Cohesin rings surrounding the chromosomes
contribute to proper formation of the SC. Stromal antigen 3 (STAG3), Recombination 8 (REC8),
Structural Maintenance of Chromosomes 1B (SMC1B), and Radiation Sensitive 21-Like
(RAD21L) encode proteins belonging to the cohesin family and are specific to meiosis. Exome
sequencing revealed that the two copies of STAG3 are inactivated by a truncating mutation in
patients with POI from a consanguineous family [26]. Of note, one patient had bilateral ovarian
tumors. Inactivation of Stag3 in mice impairs meiotic progression and leads to oocyte death
[27]. SMC1B and REC8 have also been proposed to be associated with POI [28]. The SC is
formed by several proteins organized in lateral and central elements [25]. A homozygous
mutation of the Synaptonemal Complex Central Element Protein 1 (SYCE1) was described in
two sisters with POI in a consanguineous family [29], consistent with infertility observed in
animal models [30].
Mini Chromosome Maintenance 8 and 9 are helicase members of the MCM family. MCM8-9
complex is required for homologous recombination (HR)-mediated repair of DSB, facilitat-
ing DNA resection by the MRN complex [31]. Lack of Mcm8 or Mcm9 in mice induces meiotic
defects, oocyte degeneration, and ovarian tumors. Regarding MCM8, the analysis of three
consanguineous sisters with hypothyroidism and POI revealed the presence of a pathogenic
variant [32]. The study of several other consanguineous families allowed the identification of
homozygous variants for MCM8 and MCM9 in the affected patients [33–36].
For MCM8 and MCM9, the repair of chromosomal breaks in fibroblasts or lymphocytes of the
patients was found to be altered [32,33].
Meiotic DSB repair requires the loading of two recombinases, RAD51 and its meiotic paralog DMC1,
on DNA. The activities of DMC1 and RAD51 are regulated by many factors, including homologous-
pairing protein 2 homolog (HOP2/PSMC3IP). Only one homozygous mutation in DMC1 has been
reported in women with POI [37]. The study of a Palestinian family using homozygosity mapping and
NGSallowedthedetectionofahomozygousmicrodeletion in thePSMC3IPgene[38].Thepossibility
of a meiotic defect in the patients studied was not examined directly.
The recombination intermediates need to be stabilized to promote the formation of crossovers.
This step requires helicases such as HFM1 and the dimer MSH4-MSH5. Exome sequencing
has uncovered composite heterozygous mutations in HFM1 in a cohort of patients with
sporadic POI and SA [39,40], in agreement with the phenotype of the hfm1-/- mice. Exome
sequencing recently identified a deleterious homozygous donor splice-site mutation in MSH4 in
a case of familial POI. This mutation was associated with the generation of internally deleted
MSH4 protein [41]. Similarly, a homozygous mutation in MSH5 in two sisters with POI has
recently been reported [42]. The adverse effect of this mutation was confirmed in a mouse
model and proven to impair DNA repair.
The final step of recombination is the resolution of recombination intermediates. The resolution
of the double Holliday junctions is believed to rely on the heterodimer MLH1-MLH3, and the
exonuclease EXO1. Mice lacking either Mlh1 or Mlh3 are sterile. Human mutations reported in
MLH1 are largely associated with colorectal cancer and Lynch syndrome, with no systematic
impact on fertility.
Three RecQ helicases, namely BLM (Bloom syndrome), RECQL4 (RecQ protein-like 4), and
WRN (Werner syndrome) are proposed to be involved in meiotic recombination, albeit their
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function in mammals is not fully elucidated. These RecQ helicases are also mutated in human
syndromes manifesting in premature aging, cancer, and often POI or reduced fertility [43–45].
Cockayne Syndrome B (CSB/ERCC6) encodes a protein involved in DNA repair. A heterozy-
gous mutation in the CSB-piggyBac transposable element derived 3 (PGBD3) fusion gene-
induced POI with the mutated protein exhibiting an altered response to DNA damage [46].
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Figure 1. Formation of the Ovarian Reserve in Humans and Mice. (A) Chronology of female germ cell development from primordial germ cell (PGC) specification
until follicle formation (purple). Appearance of oogonia and meiotic cells are defined respectively by the blue and red lines [weeks post fertilization (wpf), days post
conception (dpc), days postpartum (dpp)]. (B) Schematic presentation of the various germ cell stages. From left to right, migratory PGCs, oogonia, and pre-leptotene-,
leptotene-, zygotene-, pachytene-, and diplotene-arrested oocytes in primordial and growing (primary) follicles are presented in blue. Key signaling pathways regulating
PGC specification, meiotic entry, and follicle activation are provided in green. (C) Frequently used markers of the various germ cell stages. POU5F1 (OCT4), POU class 5
homeobox 1, and TFAP2C (AP2 g) are retrieved in PGC and oogonia with stem cell potential. Deleted in azoospermia-like (DAZL) and DDX4 (VASA), DEAD box
polypeptide 4, mark the gametogenic competency acquired when mouse germ cells colonize the gonad and later during oogonial differentiation in the human ovary.
STRA8 is expressed at the mitotic/meiotic switch, in the pre-leptotene stage, and SYCP3 is a synaptonemal complex protein that labels the axes of the chromosomes
during meiotic prophase I. NOBOX, NOBOX oogenesis homeobox, and tumor protein 63 (TP63), are retrieved in the nuclei of diplotene-arrested oocytes enclosed into
follicles. BMPs, Bone morphogenic proteins; CYP26B1, cytochrome P450, family 26, subfamily B, polypeptide 1; FOXO3, forkhead box O3; KITL, kit ligand; PI3K,
phosphoinositide-3-kinase; PRDM, PR domain containing 1, with ZNF domain (PRDM1/BLIMP1); PTEN, phosphatase and tensin homolog; RA, retinoic acid; STRA8,
stimulated by retinoic acid 8.
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Lastly, although meiotic DSB repair appears to rely on HR, a second process for DSB repair, the
nonhomologous end-joining (NHEJ), allows the direct ligation of broken DNA ends to each
other. X-ray repair cross-complementing protein 4 (XRCC4) and Ligase 4 (LIG4) are two
proteins absolutely required for NHEJ. Syndromic POI was reported in a female patient with
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Figure 2. Human Genes Associated with Primary Ovarian Insufficiency and Their Physiological Importance in Oogenesis, Folliculogenesis, and
Other Functions. Genes with in vivo mutations associated with primary ovarian insufficiency (POI) in humans and the physiological importance of these genes in
ovarian function are indicated. Oogenesis and folliculogenic processes are represented by a transit between different compartmental stages, depicted as boxes
containing the cell populations. At each stage of oogenesis and folliculogenesis, an important part of the germ cell will die by apoptosis, depicted by a concomitant
decrease in box sizes. The first compartment (yellow box) corresponds to the primordial germ cells (PGCs) when they differentiate into oogonia, the second
compartment (green box) corresponds to follicle formation, which involves meiosis and follicular assembly processes and ends with establishment of the ovarian reserve
of primordial follicles (pink box). From this reserve, follicular activation leads to the formation of primary follicles (light blue box). Then the growing follicles can reach the
antral stage (dark blue box) and ovulate, or degenerate by atresia. Genes whose mutations are associated with POI are indicated at each stage of these developmental
processes. The involvement of each gene at a specific stage of ovarian or follicular development is based on in vivo (presence/absence of follicles in biopsy samples,
detection of antral follicles using ovarian ultrasound scanning or AMH measurements in women carrying mutations) or/and in vitro observations (culture experiments
using human ovarian cortex or granulosa cells). For genes depicted in italic, information on their stage specific role is only available from mouse models. Genes
associated with POI for which the stage-specific role is unknown are listed in the box, with their biological function (green font). The stimulating and inhibiting factors are
depicted in black and red font, respectively. See text for references and [13].
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Table 1. Clinical Presentations of Syndromic POI.a
Diagnosis Menstrual
history
Ovarian phenotype Particular features OMIM # Gene(s) involved
WT1-related XX-DSD PA or SA Streak gonads,
partial ovarian dysgenesis
Nephropathy, diaphragmatic hernia 194070 WT1
SF1-related XX-DSD PA or SA Streak gonads,
partial ovarian dysgenesis
Adrenal insufficiency 612964 NR5A1/SF1
BPES PA or SA Rare or absent follicles Blepharophimosis, ptosis, epicanthus
inversus
110100 FOXL2
FMR1 premutation SA Follicle depletion X-linked mental retardation in family. Fragile X
tremor/ataxia syndrome
300624 FMR1
Autoimmune
polyendocrinopathy
syndrome. APS-PGA
type 1
PA or SA Autoimmune oophoritis Addison disease, candidiasis, vitiligo,
hypoparathyroidism, diabetes mellitus,
hepatitis, malabsorption, keratopathy,
alopecia
240300 AIRE
Autoimmune APS-
PGA type 3
Autoimmune oophoritis Autoimmune thyroid disease, atrophic
gastritis, vitiligo
Pseudohypopara
thyroidism
SA Follicular cysts but no
corpora lutea in one case
Brachydactyly, short stature, hypocalcemia
and hyperphosphatemia, hypothyroidism,
obesity
#103580 GNAS
Galactosemia PA Streak ovaries or few
nonmaturated follicles
Neonatal jaundice, failure to thrive, cirrhosis,
cataract, intellectual disability, food
intolerance, hypoglycemia, renal dysfunction.
230400 GALT
Disorders of
glycosylation (CDG1A)
PA Absent ovaries in some
patients by US or
laparoscopy
Growth retardation, microcephaly,
encephalopathy, peripheral neuropathy,
retinitis pigmentosa, cardiac myopathy,
hepatomegaly, nephrotic syndrome,
psychomotor retardation
212065 PMM2
Ataxia telangiectasia PA Cerebellar ataxia, telangiectasia, recurrent
infections, malignancies, and increased levels
of alpha fetoprotein
208900 ATM
Nijmegen breakage
syndrome
PA or SA Streak gonads, small ovaries Prenatal growth retardation, progressive
mental deterioration, microcephaly, recurrent
infections, increased risk for neoplasias such
as lymphoma
251260 NBN
Fanconi anemia PA or SA Decreased number of
primordial follicles
Pancytopenia, small stature, microcephaly,
ear anomalies, heart defects, kidney
malformations, radial aplasia and thumb
deformities, intellectual disability, café-au lait-
spots
#227650
#227645
#614082
FANCA
FANCC
FANCG
XRCC4-related
disorder
SA Short stature, microcephaly, developmental
delay, diabetes mellitus
#616541 XRCC4
Bloom syndrome SA Possibly accelerated follicular
atresia
Premature aging with chromosomal
instability, short stature, skin rashes and
telangiectatic skin on sun-exposed areas,
increased risk for neoplasias,
immunodeficiency
#210900 BLM
Werner syndrome SA Possibly accelerated follicular
atresia
Premature aging with chromosomal
instability, pre- and postnatal growth
deficiency, sclerodermic skin changes,
cataract, arteriosclerosis, increased cancer
risk, diabetes mellitus
#277700 WRN
Rothmund-Thomson
syndrome
SA Gonadotropin resistance Short stature, cataract, saddle nose, teeth
anomalies, premature graying of hair
#268400 RECQL4
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homozygous single nucleotide variant in the XRCC4 gene [47]. POI was reported in two patients
with biallelic truncating mutations in the LIG4 gene [48]. These patients display short stature,
microcephaly, and genomic instability or hypersensitivity to radiation. Similarly, another impor-
tant DNA repair pathway, the Fanconi anemia (FANC) pathway, exists in numerous progenitor
cells, including the germline. This pathway employs at least 20 proteins, including those
encoded by the FANCA, FANC, and FANCG genes, and has been associated with POI
[49]. Mouse models for several Fanc genes (a, c, d, e, f, g, i, m, n, o, p) evidenced gonadal
hypoplasia with ovaries showing follicle depletion [50]. This appears to be due to reduced PGC
numbers, though meiotic roles are also possible. Very recently a homozygous FANCM muta-
tion was shown to underlie a familial case of nonsyndromic POI [51]. FANCM biallelic mutations
predispose to cancer, in particular early-onset breast cancer in females and chemosensitivity
Table 1. (continued)
Diagnosis Menstrual
history
Ovarian phenotype Particular features OMIM # Gene(s) involved
Hutchinson-Gilford
progeria
SA Diminished follicular reserve Progeria, short stature, low body weight, early
loss of hair, lipodystrophy, scleroderma,
decreased joint mobility, osteolysis,
cardiomyopathy
#176670 LMNA
GAPO SA Follicle depletion Growth retardation, alopecia,
pseudoanodontia, optic atrophy, high
forehead, midface hypoplasia
#230740 ANTXR1
Perrault syndrome PA, SA Streak ovaries,
lack of ovaries,
small ovaries
Deafness
Neurologic symptoms in PRLTS1, PRLTS3,
and PRLTS5
#233400
#614926
#614129
#615300
#616138
HSD17B4, HARS2,
LARS2 CLPP
C10orf2, CLDN14+
SGO2
KIAA0391
ERAL1
Woodhouse-Sakati
syndrome
PA Streak ovaries Alopecia, deafness, hypogonadism, diabetes,
intellectual disability
#241080 C2orf37
Vanishing white matter
disease
Ovarioleukodystrophy
SA Ovarioleukodystrophy
streak ovaries
Progressive cerebellar ataxia, spasticity,
cognitive impairment with white matter
lesions on brain imaging. Onset from early
infancy to adulthood
#603896
#615889
EIF2B
AARS2
Retinal dystrophy with
or without extraocular
anomalies
SA Retinal dystrophy, goiter, intellectual
disability, hypogonadism
#617175 RCBTB1
Progressive external
ophthalmoplegia
SA Diminished follicle reserve Ptosis, progressive external ophthalmoplegia,
sensorineural hearing loss, axonal
neuropathy, muscle weakness, ataxia,
dysarthria, dysphagia and late onset
Parkinsonism
#157640 POLG
Acromesomelic
chondrodysplasia with
genital anomalies
PA Severe brachydactyly with radial deviation of
the fingers, ulnar deviation of the hands,
fusion of the carpal/tarsal bones, aplasia of
the fibula, bilateral clubfeet with small broad
feet and short toes
#609441 BMPR1B
Interphalangeal joint
synostosis
SA Symphalangism, hearing loss #185800 NOG
aDSD, Disorder of sexual differentiation; PA, primary amenorrhea; SA, secondary amenorrhea; US, ultrasound. See text for references and [13].
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[52–54]. These findings clearly support a genetic link between infertility and DNA repair/cancer
genes.
The recent identification of a genetic link between POI and tumor/cancer susceptibility genes
(STAG3, MCM9, FANCM) makes the genetic diagnosis of all isolated cases of unexplained POI
necessary, to perform enhanced genetic counseling and long-term follow-up. Indeed, POI
patients can harbor mutations in such ‘cancer susceptibility’ genes. The large number of genes
potentially involved will make these families among the most important involved in POI.
Crossover
Double strand
breaks
Homology search
RAD51, DMC1, RPA,
MEIOB, SPATA22,
BRCA2, RAD54, MND1,
PSMC3IP,  RAD52,
FMR1, BRCA1, ATR,
ATM
PRDM9, SPO11,
TOPVIBL, MEI1, MEI4,
REC114, IOH1,
HORMAD1
MCM8, MCM9, RNF212,
HEI10, MSH4, MSH5,
HFM1, TEX11
StabilisaƟon
Non-crossover
BLM,
TOP3,
RMI1
MRE11, RAD50,
NBN, RBBP8, EXO1
MLH1, MLH3, EXO1
Synaptonemal complex
Central element Lateral elements
SYCE1,
SYCP1,
SIX6OS1,
SYCE2,
TEX12
Cohesins
SYCP3,
SYCP2
STAG3,
RAD21L,
REC8,
SMC1B,
SMC3
(A)
(B) 
(C) 
(D) 
(E) 
FANCM 
Figure 3. Female Infertility, Meiotic Recombination, and DNA Repair. The various steps of meiotic recombination and the specific genes involved
(nonexhaustive, middle panel) are presented in the middle panel. Genes suspected in primary ovarian insufficiency cases are in bold. Left panel shows the structure
of the synaptonemal complex required for completing recombination. Right panel presents representative germ cells at oogonial (A), leptotene (B), zygotene (C),
pachytene (D), and diplotene (primordial follicle) (E) stages, from human ovaries at 8, 12, 15, 21, and 27 weeks postfertilization, respectively.
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Genes Involved in Syndromic POI (Figures 2 and 3 and Table 1)
The clinical presentations of syndromic POI are highly variable and are presented in Table 1.
Perrault Syndrome (PS)
Perrault syndrome (PS) is a genetically heterogeneous autosomal recessive syndrome, mainly
characterized by ovarian dysfunction and sensorineural deafness (Table 1). Recently, a
growing number of genes involved in PS were identified by NGS. These genes are implicated
in mitochondrial functions or metabolism. In mouse models, genetic changes that cause
perturbation in mitochondrial protein translation lead to hearing loss as a result of tissue-
specific apoptosis [55]. Given the role of apoptosis in ovarian development, inappropriately
timed apoptosis may also lead to POI. HARS2 [56] and LARS2 [57,58] encode mitochondrial
histidyl or leucyl-tRNA synthetases involved in translation of mitochondrially encoded genes.
CLPP encodes a highly conserved endopeptidase component of a mitochondrial ATP-
dependent proteolytic complex, involved in degradation of unfolded or misfolded polypep-
tides [59–61]. C10orf2 encodes Twinkle, a mitochondrial primase-helicase essential for
mitochondrial DNA replication [62,63], yielding a mitochondrial DNA depletion syndrome
and progressive external ophthalmoplegia. Very recently, mutations of ERAL1 and KIAA0391
were involved in PS. ERAL1 protein binds to the mitochondrial 12S rRNA and is involved in
assembly of the small mitochondrial ribosomal subunit affecting mitochondrial respiration and
function [64]. KIAA0391 encodes RNase P (PRORP) the metallonuclease subunit of the
mitochondrial RNase P complex responsible for the 50-end processing of mitochondrial
precursor tRNAs [65].
Apart from mitochondrial functions, mutations in a multifunctional peroxisomal enzyme involved
in fatty acid ß-oxidation and steroid metabolism, 17b-hydroxysteroid dehydrogenase type 4
[HSD17B4, also known as D-bifunctional protein (DBP)] also cause PS [66–68]. Mutations of
this gene were already identified in autosomal recessive mode in a severe disorder of peroxi-
somal fatty acid b-oxidation.
A combination of two homozygous mutations leading to a coincidental PS, one in CLDN14
involved in deafness and the other in shugoshin-like 2a (SGO2) encoding shugoshin2, likely
involved in POI, have been described [69]. During meiosis in the mouse, SGO2 maintains the
integrity of the cohesion complex that tethers sister chromatids. Unsolved cases of PS persist,
indicating that novel genes will still be discovered [70,71].
Premature Aging Syndromes
Laminopathy due to mutations in LMNA encoding a nuclear envelope protein includes ovarian
failure and premature aging. Malouf syndrome belongs to this condition [72]. Hutchinson-
Gilford progeria Syndrome (HGPS) [73], caused by aberrant splicing of the LMNA gene and
expression of a mutant product called progerin, comprises premature aging and lipodystro-
phies. Sometimes both syndromes occur together [73].
GAPO syndrome, another form of premature aging and premature follicle depletion, is caused
by mutations of the anthrax toxin receptor 1 gene ANTXR1 [74]. The protein has been involved
in cell attachment and migration. Additionally, it allows the interaction of cells and several
components of the extracellular matrix by binding extracellular ligands with the actin of the
cytoskeleton.
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Neurosensory Syndromes
Leukoencephalopathies are also a heterogeneous group of disorders associated with vanish-
ing white matter and are seen in a subset of POI, yielding ovarioleukodystrophy. Mutations of a
specific mitochondrial alanine aminoacyl-tRNA synthetase, AARS2, have been involved
[75,76]. Another group of genes involved is EIF2B1 to EIF2B5 which encode the five subunits
of the eukaryotic initiation factor 2B [77].
Mutations in RCBTB1 [78] are present in syndromes including inherited retinal dystrophy and
POI. RCBTB1 is involved in ubiquitination, more specifically as a CUL3 substrate adaptor
involved in stress-response to combat oxidative or electrophilic insults.
Mutations of the nuclear gene POLG encoding a mitochondrial DNA polymerase gamma can
lead to POI with autosomal dominant progressive external ophthalmoplegia [79].
Defects in the respiratory chain or mitochondrial ATP synthase (complex V) result in mitochon-
drial dysfunction and defective energy production. Mutations of MT-ATP6/8 encoding two of
the subunits of complex V are associated with syndromes including cerebellar ataxia, peripheral
neuropathy, diabetes mellitus, and POI [80].
Skeletal Syndromes
POI can occur in some skeletal syndromes, such as Demirhan syndrome, which is caused by
mutations in BMPR1B [81].
Another condition including proximal symphalangism and POI is caused by mutations in NOG
[82]. NOG protein is expressed in the ovaries and interacts with BMP, which plays an important
role in ovarian function.
Genes Associated With Nonsyndromic POI
See Figures 2 and 3.
Regulation of PF Recruitment
The majority of PF will remain dormant until stimulatory signals or a break from inhibitory signals
induces activation. PF recruitment is initiated in mice after birth at postnatal day 4–5, and in
humans at 17 weeks of gestation (Figure 1).
Various oocyte-expressed signaling and/or transcription factors have been identified to main-
tain the quiescent state (Foxo3, Lhx8) or, in contrast, to activate PF growth (Sohlh1, Sohlh2,
Nobox) [83] (Figure 2). Interestingly, Foxo3 and Lhx8 are the effectors of the PI3K/Akt
signaling pathway [84]. Targeted (oocyte-specific) deletion of stimulating factors (Kit, Pdpk1,
Rptor, Rps6) of this pathway blocks follicular activation and induces PF apoptosis, whereas
loss of the inhibiting factors (Pten, Cdkn1b, Tsc1, Tsc2, Stk11) results in premature and global
activation of PF [85] (Figure 2).
A characteristic of PF activation is the transition of squamous pregranulosa cells to cuboidal
granulosa cells. Failure thereof results in an arrest at the primordial stage, followed by oocyte
death and follicular depletion, as shown in FoxL2 knockout mice [86]. AMH, expressed during
this transition, inhibits PF activation since Amh knockout mice display an accelerated exhaus-
tion of the pool [87]. Several additional growth factors have been shown to activate PF
recruitment (Figure 2).
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Regulation of Follicle Growth
Gonadotropin-Independent Phase: Role of Ovarian Growth Factors; Early follicle growth up to
the large preantral stage is independent of gonadotropins in rodents and relies on intraovarian
factors (Figure 2). It requires a coordinated dialog between the oocyte and granulosa cells, in
which gap junctions and SMAD and PI3K/Akt pathways are important. The discovery that
follicles in ovaries of Gdf9 knockout mice fail to develop beyond the primary stage was the first
of a series showing the importance of factors involving SMAD signaling pathway in follicle
development [88]. Furthermore, in the oocyte-knockout of Furin, a prohormone convertase
responsible for proteolytic cleavage of TGFb family members, follicle growth is arrested at the
secondary stage [89]. Likewise, inhibition of the PI3K/Akt pathway by Kit or Kitlg deletions leads
to the blockage of follicular growth at the primary follicle stage. Using targeted deletion or
activation of Igf1, Igf1r, Irs2, Rictor, or Foxo3, it was shown that the PI3K/Akt signaling pathway
not only plays a role in PF activation, but also in follicle survival and development beyond the
primary stage [90,91] (Figure 2).
Gonadotropin-Dependent Phase: Role of Gonadotropins; The progression through final stages
of follicle development depends on the gonadotropins FSH and luteinizing hormone (LH)
(Figure 2). The threshold for FSH sensitivity is determined by interplay between various
stimulatory and inhibitory growth factors, such as IGF1 and various TGFb family members
tipping the balance to either follicle survival or atresia. Deletion of the Fshr yields an enhanced
rate of atresia and follicles fail to progress to the antral stage [92]. Targeted deletion of the
noncanonical progesterone receptor Pgrmc1 in granulosa cells suppressed antral follicle
development and increased atresia [93]. Finally, LH action is indispensable for ovulation,
meiotic resumption of the oocytes, and cumulus expansion. Loss of LH action therefore also
results in infertility as follicle development is blocked at the antral stage [94]. In the absence of
sex steroid action, the final stages of follicle development show abnormalities leading to
follicular arrest, as illustrated in mouse models lacking (cell-specific) androgen or estrogen
function [95,96].
Defects in Human Genes in Nonsyndromic POI
Interestingly, there is an overlap between genes involved in the onset of puberty, normal
reproductive aging, and POI [97]. We will present only recent data or selected examples of
genes that illustrate the precaution that must be taken in the interpretation of genetic data and
comparison with animal models.
Genes Involved in Establishment of the PF Pool and Maturation to Primary Follicles;
Heterozygous variants of SOHLH1 and SOHLH2 have been found in POI [98]. Interestingly, two
families harboring a homozygous single-base deletion in the coding region or a premature stop
codon of SOHLH1 [99] had PA, lack of secondary sex characteristics, and nonvisualized
ovaries.
A recessive missense mutation in Nucleoporin-107 was identified in a consanguineous family of
Palestinian origin [100]. NUP107 is a component of the nuclear pore complex, and the
NUP107-associated protein SEH1 is required for oogenesis in Drosophila. In Drosophila,
Nup107 knockdown in somatic gonadal cells resulted in female sterility, whereas males were
fully fertile. Nup107 mutations may compromise the meiotic DNA damage response, leading to
oocyte death.
A heterozygous stop codon was identified in the eukaryotic translation initiation factor 4E
nuclear import factor 1 gene eIF4ENIF1 in familial POI with dominant inheritance in three
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generations [101]. The gene plays an important role in oocyte development in organisms from
Drosophila to mice.
Heterozygous mutations of the Newborn ovary homeobox (NOBOX) transcription factor have
been reported in women with sporadic POI [28,102,103]. Contrasting with the knockout mouse
model, which displays accelerated postnatal oocyte loss due to a defect in germ cell cyst
breakdown [104], patients with NOBOX mutations may have PA or SA with follicles detected by
histology in the ovaries in adulthood [102]. This may be due to the fact that the human mutations
caused only partial loss of function in vitro. Functional studies are thus critical before any
comparison with animal models and before any conclusion on the human physiological role of a
gene can be established. Interestingly, a prevalence of 5.6% and 6.2% of heterozygous
mutations has been detected in different cohorts, making this gene potentially one of the
most frequent causes of POI in humans, provided that causality of the heterozygous variants is
proven. Recently, a homozygous truncated variant of NOBOX has been described [105], with
complete loss of function in vitro in patients with PA, but with no ovarian phenotype. Fertility of
the heterozygous mother excludes a mechanism of haploinsufficiency, as previously proposed.
Genes Involved in the Maturation and Growth from Primary to Ovulatory Follicles;
The two steroid hormone receptors, for estrogens (ESR1) and androgens (AR), are positive
regulators of follicular maturation. Two families with homozygous mutations of ESR1 have been
described. The probands had PA without breast development, very high estrogen plasma
concentrations, and multicystic ovaries [106,107]. Functional studies reveal altered estrogen
signaling.
Interestingly, a continuum of phenotypes is associated with FSHR mutations, varying from
absence of pubertal maturation to normal breast development with SA, according to severity of
the receptor inactivation [108–111]. The first mutation described in the Finnish population was
associated with the existence of preantral or rare antral follicles in the ovaries [108]. However,
functional studies have shown that it was a partial loss of function mutation [112]. A complete
loss of function mutation of the FSHR has also been described, causing PA and complete block
of follicular maturation after the primary stage [113]. Remarkably, there was an increased
density of small follicles when compared with an age-matched woman. Thus, the gonadotro-
pin-dependent growth phase in humans starts at the primary follicle stage, contrary to rodents,
in which preantral follicles are observed in ovaries of mice deficient in Fshb or Fshr (see above).
Thus caution must be taken before extrapolating data from mouse models to humans. Partial
mutations of the FSHR are associated with SA and the presence of different sized antral
follicles, depending on severity of the mutation [114]. Of note, there is a correlation between the
phenotype of the patients and the molecular studies. Because of the existence of follicles in the
ovaries, in vitro maturation may be obtained and fertility restored ([115] and see below).
Mutations in the other gonadotropin receptor gene, LHCGR, cause POI with SA, anovulation,
and recurrent cyst formation. In the affected families, disorders of sex differentiation are found in
male relatives with hypogonadism due to Leydig cell hypoplasia [116,117].
The first involvement of BMP15 in POI was reported in an Italian family with 46,XX ovarian
dysgenesis [118]. Since then, several heterozygous and one homozygous BMP15 variant have
been associated with PA or SA, but streak ovaries without follicles have been found using US,
which was interpreted as premature depletion of the OR [118]. Functional studies suggest
impaired production of the mature protein or, in some cases, a dominant negative effect [118].
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However, most of the variants detected occur in the heterozygous state, and BMP15 hap-
loinsufficiency was proposed to have a predisposing impact for POI. It was also proposed that
reduced BMP15 dosage would contribute to the ovarian phenotype of Turner syndrome
patients [119]. These conclusions were challenged by a very recent work on a family with a
BMP15 knockout-like effect [120], with both parents bearing deletions in the proregion of the
BMP15 precursor. The heterozygous mother conceived normally and had three children. Thus,
it seems that haploinsufficiency is not involved in humans. Most of the mutations of BMP15
described were heterozygous and a mechanism of haploinsufficiency or a dominant negative
effect was suspected but most often not demonstrated, making it impossible to implicate the
corresponding gene as the unique cause of POI. Additional genetic mutations in an oligogenic
mode of inheritance and/or environmental factors must be involved. Despite streak ovaries,
AMH was initially detectable in the two POI sisters bearing both deletions of BMP15, supporting
the presence of an OR [120]. Five years later, however, AMH was not detected in both sisters,
probably because of exhaustion of the PF pool, and one sister had received an egg donation.
In case POI is due to a block in follicular maturation, urgent fertility preservation is needed to
avoid follicular atresia.
A recent study showed a homozygous single-base deletion in the coding region of GDF9 in POI
with PA [121], confirming the causative role of this gene.
Innovative Treatments for POI
The most frequent therapeutic approach of infertility of POI patients is embryo transfer from
donated oocytes. Given the complexity of this therapeutic approach, couples requiring oocyte
donation should discuss its medical, ethical, legal, and psychological aspects with medical
experts. Recently, a new innovative fertility treatment has been developed for POI (Figure 4).
Premature activation of PFs caused by chemotherapy, particularly cyclophosphamide, is a
significant cause of the disappearance of follicles from the ovaries. Fertility preservation through
tissue cryopreservation before chemotherapy is therefore an important method for preventing
POI [122]. Post-treatment, the tissue can be autotransplanted. Infants have been born as a
result of the technique.
For cancer patients at high risk of reintroduction of the malignancy, such as leukemia, in vitro
maturation of follicles all the way to metaphase II oocytes is a much needed therapy that still
remains to be developed.
In early stages of ovarian insufficiency there are PFs left in the ovaries. Hence, cryopreservation
of ovarian tissue as fertility preservation should be carried out as soon as the risk of follicular
decrease has been identified. Although these PFs are inactive, Hovatta et al. [123] showed that
human ovarian follicles can be activated when ovarian tissue is cut into small pieces and placed
in organ culture. Recently, Hippo signaling was identified as the regulatory factor in this
activation [5,124]. When residual follicles in ovarian tissue from POI patients were stimulated
by cutting the tissue into small pieces, and subsequently exposed to phosphatase and tensin
homolog (PTEN) inhibitors and protein kinase B (Akt) activators prior to transplantation, full
oocyte maturation can be achieved [125] (Figure 4). Of note, PTEN is also an important tumor
suppressor, and therefore its inactivation in vivo might be risky. After IVA, the follicles have to be
stimulated to grow, and FSH stimulation is used in a similar manner as in ovulation induction or
before in vitro fertilization treatments. The ovarian tissue has been transplanted back to patients
after IVA and healthy infants have been born (Figure 4). This IVA method is useful for those
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patients who may have residual follicles left in their ovaries (see flow chart in Figure 5 for POI
diagnosis and treatment).
Ultimately, recent technological developments with induced pluripotent stem cells allow the
reconstitution of complete oogenesis [126]. Currently this has only been achieved in the mouse,
but advances with human cells now make it conceivable for modeling POI and would prove
invaluable for supporting genetic diagnosis. In specific cases (e.g., altered follicle recruitment or
growth), such models may prove useful for drug screening and selecting the most appropriate
treatment.
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Figure 4. In Vitro Activation of Dormant Follicles. Ovarian cortical tissue is laparoscopically biopsied from the woman undergoing primary ovarian insufficiency
(POI). The tissue is cut into slices for activation of Hippo signaling and initiation of follicular growth. Sliced tissue is then activated using a PTEN inhibitor or AKT stimulator
in vitro for 24 hours. Thereafter, the tissue pieces can be transplanted back to the ovary of the donor woman. The activated follicles are stimulated using human
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activation; IVF, in vitro fertilization.
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Other technological developments, such as tissue engineering to generate ovarian implants,
are promising leads that may help restore fertility [127].
Concluding Remarks and Future Perspectives
Taken together, the vast technological advancements have provided valuable new information
on the molecular pathophysiology of POI and its new diagnosis and treatment opportunities.
Information derived from recent genetic studies has improved the accuracy of POI diagnosis
and may reveal new targets for the treatment of infertility or for contraception in the future.
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Figure 5. Flow Chart for Primary Ovarian Insufficiency Diagnosis and Treatment. After the initial diagnosis of primary ovarian insufficiency (POI), family
investigation and evaluation of the follicular reserve by anti-Müllerian hormone (AMH) assay and antral follicular count (AFC) are performed. Specific causes are
eliminated. In the case of unexplained POI, karyotype and FMR1 study are performed. In all cases hormonal treatment has to be started. In isolated POI, array
comparative genomic hybridization (aCGH) or next generation sequencing (NGS) can highlight defects in genes involved in ovarian differentiation or in the establishment
of the follicular pool. This, together with the undetectable ovarian reserve, will lead to genetic counseling in the patient and relatives and therapeutic counseling for the
patient’s infertility by a multidisciplinary team. If there is a wish to conceive, egg donation will be performed. In the case of a detectable ovarian reserve and/or a defect in
genes involved in follicular maturation, genetic counselling will be performed in the patient and relatives and therapeutic counseling will lead to fertility preservation. In the
future, in vitro activation (IVA) of small follicles might be performed. In syndromic POI, NGS of specific genes will be performed according to the clinical phenotype of the
patient. Specific treatment of associated symptoms is needed. AFC antral follicle count; DSD, disorder of sexual differentiation; FSH, follicle-stimulating hormone; PA,
primary amenorrhea; PRL, prolactin; PTH, parathyroid hormone; SA, secondary amenorrhea; TSH, thyroid-stimulating hormone; US,ultrasonography; VWM, vanishing
white matter.
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Because of its increased nonreproductive morbidity and mortality (e.g., autoimmunity and
tumors) POI should be followed by a multidisciplinary team. The very recent identification of a
link between POI and tumor susceptibility makes the genetic diagnosis of all isolated cases of
unexplained POI necessary. Also, POI as a genetic disorder becomes amenable to innovative
therapies, unlike most other genetic diseases. This obviously necessitates the presence of
remnant OR that has to be evaluated besides conventional methods by genetic studies
(Figure 5). Indeed, the key question is: what is the state of the follicular pool in the POI patient?
The mutated gene may provide important information on the OR, depending on its level of
action during either establishment and/or maintenance of the follicular pool, or follicular growth.
This belongs to the questions that will need to be answered in the future (see Outstanding
Questions).
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